Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model.
Journal: JCO clinical cancer informatics
Published: June 23, 2023
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 25, 2023
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 25, 2023
Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
Journal: Pediatric blood & cancer
Published: April 14, 2015
Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Journal: Annals of the New York Academy of Sciences
Published: August 08, 2014
Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Journal: Pediatric blood & cancer
Published: September 17, 2013
Showing 1-7 of 7
Last Updated: 09/26/2026